CN116710169A - 整合素抑制剂及其用途 - Google Patents

整合素抑制剂及其用途 Download PDF

Info

Publication number
CN116710169A
CN116710169A CN202180090550.5A CN202180090550A CN116710169A CN 116710169 A CN116710169 A CN 116710169A CN 202180090550 A CN202180090550 A CN 202180090550A CN 116710169 A CN116710169 A CN 116710169A
Authority
CN
China
Prior art keywords
crystalline form
water content
peaks
xrpd pattern
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180090550.5A
Other languages
English (en)
Chinese (zh)
Inventor
J·查
K·莱夫特里斯
G·齐
J·王
D·赵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pliant Therapeutics Inc
Original Assignee
Pliant Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliant Therapeutics Inc filed Critical Pliant Therapeutics Inc
Publication of CN116710169A publication Critical patent/CN116710169A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35—Naphthalene sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202180090550.5A 2020-11-19 2021-11-19 整合素抑制剂及其用途 Pending CN116710169A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063116042P 2020-11-19 2020-11-19
US63/116,042 2020-11-19
PCT/US2021/072510 WO2022109598A1 (en) 2020-11-19 2021-11-19 Integrin inhibitor and uses thereof

Publications (1)

Publication Number Publication Date
CN116710169A true CN116710169A (zh) 2023-09-05

Family

ID=81709878

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180090550.5A Pending CN116710169A (zh) 2020-11-19 2021-11-19 整合素抑制剂及其用途

Country Status (19)

Country Link
US (2) US12018025B2 (enExample)
EP (1) EP4247472A4 (enExample)
JP (1) JP2023550428A (enExample)
KR (1) KR20230121761A (enExample)
CN (1) CN116710169A (enExample)
AU (1) AU2021381516A1 (enExample)
CA (1) CA3173755A1 (enExample)
CL (1) CL2023001418A1 (enExample)
CO (1) CO2023006522A2 (enExample)
CR (1) CR20230262A (enExample)
CU (1) CU20230026A7 (enExample)
DO (1) DOP2023000101A (enExample)
EC (1) ECSP23045278A (enExample)
IL (1) IL302651A (enExample)
JO (1) JOP20230102A1 (enExample)
MX (1) MX2023005889A (enExample)
PE (1) PE20240114A1 (enExample)
TW (1) TW202235417A (enExample)
WO (1) WO2022109598A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE50554E1 (en) 2016-12-23 2025-08-26 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
US11419869B2 (en) 2019-04-08 2022-08-23 Pliant Therapeutics, Inc. Dosage forms and regimens for amino acid compounds
CN120091811A (zh) * 2022-07-09 2025-06-03 普利安特治疗公司 整合素抑制剂及其与其它药剂组合的用途
WO2024155965A2 (en) * 2023-01-21 2024-07-25 Pliant Therapeutics, Inc. Biomarkers for use in integrin inhibitor therapy
WO2025072206A1 (en) * 2023-09-25 2025-04-03 Pliant Therapeutics, Inc. Integrin inhibitors for treatment of primary sclerosing cholangitis
TW202535400A (zh) 2023-12-14 2025-09-16 美商普萊恩醫療公司 整合素抑制劑及其用途
WO2025217571A1 (en) * 2024-04-12 2025-10-16 Pliant Therapeutics, Inc. Fixed dose combinations of integrin inhibitor with ppar agonists

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104736178A (zh) * 2012-06-04 2015-06-24 药品循环公司 布鲁顿酪氨酸激酶抑制剂的晶形
US20190276449A1 (en) * 2018-03-07 2019-09-12 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
US20200352942A1 (en) * 2019-04-08 2020-11-12 Pliant Therapeutics, Inc. Dosage forms and regimens for amino acid compounds

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015048819A1 (en) 2013-09-30 2015-04-02 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
CA2981371A1 (en) 2015-03-10 2016-09-15 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
CN109996541A (zh) 2016-09-07 2019-07-09 普利安特治疗公司 N-酰基氨基酸化合物及其使用方法
USRE50554E1 (en) 2016-12-23 2025-08-26 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
SG11201907820SA (en) 2017-02-28 2019-09-27 Morphic Therapeutic Inc Inhibitors of (alpha-v)(beta-6) integrin
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
WO2020016704A1 (ja) * 2018-07-20 2020-01-23 株式会社半導体エネルギー研究所 撮像パネル、撮像装置
CA3109534A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibiting .alpha.v .beta.6 integrin
EP3843727A4 (en) 2018-08-29 2022-08-17 Morphic Therapeutic, Inc. INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN
ES3027421T3 (en) 2018-08-29 2025-06-13 Morphic Therapeutic Inc Inhibitors of (alpha-v)(beta-6) integrin
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
EP3903316A1 (en) * 2018-12-28 2021-11-03 LunaPBC Community data aggregation, completion, correction, and use
EP3923857B8 (en) * 2019-02-15 2024-04-17 Clean Bite, LLC Oral hygiene appliance
EP4058481A1 (en) 2019-11-15 2022-09-21 Pliant Therapeutics, Inc. Compositions and methods for activation of integrins
CN115989235A (zh) 2020-05-07 2023-04-18 普利安特治疗公司 使用氨基酸化合物治疗呼吸系统疾病的方法
TWI838626B (zh) * 2020-06-03 2024-04-11 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
WO2022087224A1 (en) * 2020-10-21 2022-04-28 Cohbar, Inc. Method of treating fibrosis with a combination therapy
CA3173787A1 (en) 2021-04-30 2022-11-03 Scott Turner Expanded dosage regimens for integrin inhibitors
US20240350494A1 (en) 2021-09-03 2024-10-24 Pliant Therapeutics, Inc. Therapeutic modulation of integrins
EP4416147A1 (en) 2021-10-14 2024-08-21 Pliant Therapeutics, Inc. Integrin inhibitors and uses thereof in combination with other agents
WO2023225119A1 (en) 2022-05-18 2023-11-23 Pliant Therapeutics, Inc. Stabilization of integrin inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104736178A (zh) * 2012-06-04 2015-06-24 药品循环公司 布鲁顿酪氨酸激酶抑制剂的晶形
US20190276449A1 (en) * 2018-03-07 2019-09-12 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
US20200352942A1 (en) * 2019-04-08 2020-11-12 Pliant Therapeutics, Inc. Dosage forms and regimens for amino acid compounds

Also Published As

Publication number Publication date
CR20230262A (es) 2023-07-26
PE20240114A1 (es) 2024-01-22
CU20230026A7 (es) 2024-01-10
ECSP23045278A (es) 2023-07-31
EP4247472A1 (en) 2023-09-27
US12018025B2 (en) 2024-06-25
US20220177468A1 (en) 2022-06-09
US20240391914A1 (en) 2024-11-28
AU2021381516A9 (en) 2024-10-24
CO2023006522A2 (es) 2023-06-09
AU2021381516A1 (en) 2023-06-22
JP2023550428A (ja) 2023-12-01
EP4247472A4 (en) 2024-10-09
CL2023001418A1 (es) 2023-10-30
IL302651A (en) 2023-07-01
DOP2023000101A (es) 2023-09-29
TW202235417A (zh) 2022-09-16
MX2023005889A (es) 2023-06-06
KR20230121761A (ko) 2023-08-21
WO2022109598A1 (en) 2022-05-27
CA3173755A1 (en) 2022-05-27
JOP20230102A1 (ar) 2023-05-08

Similar Documents

Publication Publication Date Title
US20240391914A1 (en) Integrin inhibitor and uses thereof
ES2750676T5 (en) Crystalline dihydrochloride hydrate salt of omecamtiv mecarbil and process for its preparation
KR20210013554A (ko) Tlr7/tlr8 억제제의 결정질 형태
US10150770B2 (en) Crystal form of bisulfate of JAK inhibitor and preparation method therefor
ES2610398T3 (es) Sales de derivados de pirrolopirimidinona y procedimiento para su preparación
BR112017007953B1 (pt) Forma cristalina ii do bissulfato inibidor de jak quinase, seu uso e seu método de preparação, e composição farmacêutica
CN115466252A (zh) 一种Lanifibranor的晶型及其制备方法
JP2015508090A (ja) 固体形態のダビガトランエテキシレートメシレート及びその調製方法
BR112014018763B1 (pt) Sais de adição de ácido cristalino de um derivado tricíclico ou hidratos dos mesmos e método de produção dos mesmos
JP2024517431A (ja) （ｓ）－ｎ－（３－（２－（（（ｒ）－１－ヒドロキシプロパン－２－イル）アミノ）－６－モルホリノピリジン－４－イル）－４－メチルフェニル）－３－（２，２，２－トリフルオロエチル）ピロリジン－１－カルボキサミドおよびその塩の固体状態での形態
US11325943B2 (en) Crystalline salt forms of SBT-20
PT2448945E (pt) Formas cristalinas de sais de prasugrel
US20250250268A1 (en) Free-state plx5622 crystal form and preparation method therefor
WO2015176591A1 (zh) 贝曲西班盐及其制备方法和用途
CN111971272A (zh) 柳氮磺吡啶盐组合物及其使用方法
US20250154108A1 (en) Crystal form of 7-azaspiro[4,5]decane-6,10-dione compound and preparation method therefor
US8779140B2 (en) Crystal of fused pyridine compound salt
WO2022224269A1 (en) Co-crystals, salts and solid forms of niraparib
US7655800B2 (en) Crystalline 1H-imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)-methyl]-1H-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses
WO2025124537A1 (en) Integrin inhibitor and uses thereof
CN105693699A (zh) 托吡司他的新晶型及其制备方法
CN105399725A (zh) 曲格列汀化合物其盐、晶体、药物组合物和用途
CN113840605A (zh) N-(5-((4-乙基哌嗪-1-基)甲基)吡啶-2-基)-5-氟-4-(3-异丙基-2-甲基-2h-吲唑-5-基)嘧啶-2-胺及其盐的结晶和无定形形式，及其制备方法和治疗用途
TWI922665B (zh) (s)-n-(3-(2-(((r)-1-羥基丙-2-基)胺基)-6-嗎啉基吡啶-4-基)-4-甲基苯基)-3-(2,2,2-三氟乙基)吡咯啶-1-甲醯胺及其鹽之固態形式
CN111902398A (zh) Urat-1抑制剂的新盐型

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination